Cytokine-adjuvanted HIV-DNA vaccination strategies.
This review highlights some of the most common cytokines currently being tested as adjuvants in HIV-1-DNA vaccine regimens. We discuss their use in both the prophylactic and therapeutic setting. Finally, we describe a novel dendritic cell-targeted vaccine candidate for HIV-1 treatment and prevention called DermaVir and explore the combination of the DermaVir technology with the cytokine adjuvants interleukin-7 and interleukin-15.
Lori
Franco
F
Research Institute for Genetic and Human Therapy (RIGHT), Pavia, Italy. rightpv@tin.it
Weiner
David B
DB
Calarota
Sandra A
SA
Kelly
Laurene M
LM
Lisziewicz
Julianna
J
D016915:AIDS Vaccines / Q000276:immunology / Q000627:therapeutic use; D000276:Adjuvants, Immunologic; D000818:Animals; D023241:Antiretroviral Therapy, Highly Active; D016207:Cytokines / Q000276:immunology*; D015483:HIV Antibodies / Q000096:biosynthesis / Q000276:immunology; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy*; D006801:Humans; D019444:Vaccines, DNA / Q000276:immunology / Q000627:therapeutic use
D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; D016207:Cytokines; C501366:DermaVir; D015483:HIV Antibodies; D019444:Vaccines, DNA